Maintenance, Reagents, and Supplies

The National Institute of Health, Clinical Center (CC) intends to award a BPA order to Roche Diagnostics, Indianapolis, IN 46250, to procure Bundle Operating Lease (Maintenance, Reagents, and Supply Rental). Roche Diagnostics is the only vendor/manufacturer that can provide the maintenance and full test menu required for clinical patient care testing in the NIH CC Department of Laboratory Medicine. The reagents and testing supplies requested from Roche Diagnostics are specific for the already existing family of three (3) BenchMark Ultras, one (1) BenchMark Discovery, and one (1) Ventana Special Stain analyzer. They cannot be interchanged with another vendor. Since the service, reagents, and supplies are proprietary, there is only one supplier whose products can fit into the instrumentation; any other supply or service could cause the cancellation of the protocol or delays in the completion of the protocol. The Department of Laboratory Medicine (DLM) will telephone or e-mail requests for required services and items on a needed basis. Period of Performance shall be for a base year of twelve (12) months. The contractor will supply the following products and services as required by DLM: Detection kits for three Benchmark Ultra instruments Detection kits (anticipated for new testing) for one Benchmark Discovery Bulk reagents for three Ultra's & one Discovery Ancillary reagents: Counterstains, bluing reagent, blocking reagents DNA based In Situ Hybridization staining (Kappa/Lambda ISH only) Non-reagent materials: prep kit dispensers & slide labels Antibodies: proprietary antibodies or ready to use third party antibodies Special stain kits and bulk reagents Relocation of instruments This acquisition is being conducted under the authority of the FAR Subpart 13.106-1(b)(1)(i) allowing the Contracting Officer (CO) to solicit from one source. Interested concerns capable of providing the same or similar products or services as described in this notice may submit a capability statement outlining their capabilities. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. A determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Each response should include the following Business Information: a. DUNS. b. Company Name, address, POC, Phone and Email address c. Current GSA Schedules or NAICS codes appropriate to this Award. d. Type of Company (i.e., small business, 8(a), woman owned, hubZone, veteran owned, etc.) as validated in System For Award Management (SAM). All offerors must register on the SAM located at http://www.sam.gov/portal/SAM/#1 e. Capability Statement Comments to this announcement may be submitted to the Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Kimala Winfield, contact@example.gov or Malinda Dehner, contact@example.gov by the due date and time marked in this notice.